Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

March 24-25, 2017

New York, New York

Continuing Medical Education

Continuing Medical Education
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification​
Successful completion of this CME activity enables a participant to earn up to 14.5 MOC points towards the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend
This educational activity is specifically designed to meet the educational needs of community oncologists and other healthcare professionals (physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved in the therapeutic management of patients with GI cancers.

To enhance clinical outcomes in patients with gastrointestinal malignancies, healthcare professionals require expert review and analysis of pertinent clinical data to effectively identify and integrate optimal therapeutic regimens into everyday clinical practice. To narrow the identified practice gaps and underlying educational needs, the following objectives will be addressed within the educational activities.

    • Evaluate the mechanism of action and therapeutic potential of current and novel agents, including immunotherapies, designed to manage GI malignancies
    • Interpret pertinent clinical trial data for standard of care and novel management strategies for non-metastatic and metastatic GI cancers
    • Assess how integration of relevant clinical trial data into clinical practice has the potential to enhance outcomes in patients with non-metastatic and metastatic GI cancers
    • Define patient populations who would gain the most clinical benefit from the utilization of standard of care and novel therapeutic agents
    • Formulate evidence-based strategies for the management non-metastatic and metastatic GI cancers that take into consideration patient risk factors, cost, disease stage, and prior therapeutic regimens